Scilight Press

Author Information

Received: 23 Jan 2026 | Revised: 21 Mar 2026 | Accepted: 30 Mar 2026 | Published: 08 Apr 2026

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

Lipoxygenase | vascular inflammation | leukotrienes | specialized pro-resolving lipid mediators | resolution of inflammation

References 

• 1.

  Linares, I.; Chen, K.; Saffren, A.; et al. Fluid flow impacts endothelial-monocyte interactions in a model of vascular inflammatory fibrosis. Sci. Rep. 2025, 15, 3227.

• 2.

  Uebbing, S.; Kreiß, M.; Scholl, F.; et al. Modulation of microRNA processing by 5-lipoxygenase. FASEB J. 2021, 35, e21193.

• 3.

  Kreiß, M.; Oberlis, J.H.; Seuter, S.; et al. Human 5-lipoxygenase regulates transcription by association to euchromatin. Biochem. Pharmacol. 2022, 203, 115187.

• 4.

  Ketelhuth, D.F.; Hermansson, A.; Hlawaty, H.; et al. The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE^−/− mice. Prostaglandins Other Lipid Mediat. 2015, 121, 105–109.

• 5.

  Nshimiyimana, R.; Simard, M.; Teder, T.; et al. Biosynthesis of resolvin D1, resolvin D2, and RCTR1 from 7,8(S,S)-epoxytetraene in human neutrophils and macrophages. Proc. Natl. Acad. Sci. USA 2024, 121, e2405821121.

• 6.

  Mainka, M.; George, S.; Angioni, C.; et al. On the biosynthesis of specialized pro-resolving mediators in human neutrophils and the influence of cell integrity. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2022, 1867, 159093.

• 7.

  Libreros, S.; Shay, A.E.; Nshimiyimana, R.; et al. A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution. Front. Immunol. 2021, 11, 631319.

• 8.

  Fredman, G.; Hellmann, J.; Proto, J.D.; et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 2016, 7, 12859.

• 9.

  Bay, B.; Tanner, R.; Gao, M.; et al. Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention. Eur. Heart J. 2025, 46, 3167–3177.

• 10.

  Gao, S.; Huang, S.; Liu, X.; et al. Significance of Residual Inflammatory Risk and Persistent Inflammation in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. J. Inflamm. Res. 2025, 18, 13855–13868.

• 11.

  Di Gennaro, A.; Araújo, A.C.; Busch, A.; et al. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm. Proc. Natl. Acad. Sci. USA 2018, 115, 1907–1912.

• 12.

  Chen, J.W.; Li, Y.R.; Tao, L.Y.; et al. 12/15-lipoxygenase deficiency attenuates disturbed flow-induced LDL oxidation in endothelial cells. Biochem. Biophys. Res. Commun. 2026, 794, 153010.

• 13.

  Manega, C.M.; Fiorelli, S.; Porro, B.; et al. 12(S)-Hydroxyeicosatetraenoic acid downregulates monocyte-derived macrophage efferocytosis: New insights in atherosclerosis. Pharmacol. Res. 2019, 144, 336–342.

• 14.

  Vijil, C.; Hermansson, C.; Jeppsson, A.; et al. Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLoS ONE 2014, 9, e88546.

• 15.

  Brungs, M.; Rådmark, O.; Samuelsson, B.; et al. Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1995, 92, 107–111.

• 16.

  Loesche, C.; Picard, D.; Van Hoorick, B.; et al. LTA₄H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clin. Transl. Sci. 2024, 17, e13724.

• 17.

  Elborn, J.S.; Konstan, M.W.; Taylor-Cousar, J.L.; et al. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J. Cyst. Fibros. 2021, 20, 1026–1034.

• 18.

  Basavarajappa, D.; Wan, M.; Lukic, A.; et al. Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis. Proc. Natl. Acad. Sci. USA 2014, 111, 11371–11376.

• 19.

  Dahlke, P.; Peltner, L.K.; Jordan, P.M.; et al. Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators. Front. Pharmacol. 2023, 14, 1219160.

• 20.

  Teder, T.; König, S.; Singh, R.; et al. Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A₄ Hydrolase. Int. J. Mol. Sci. 2023, 24, 7539.

• 21.

  Allen, S.; Dashwood, M.; Morrison, K.; et al. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998, 97, 2406–2413.

• 22.

  Yurdagul, A., Jr.; Subramanian, M.; Wang, X.; et al. Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. Cell Metab. 2020, 31, 518–533.e10.

• 23.

  Arnardottir, H.; Thul, S.; Pawelzik, S.C.; et al. The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. J. Clin. Investig. 2021, 131, e142883.

• 24.

  Ebert, R.; Cumbana, R.; Lehmann, C.; et al. Long-term stimulation of toll-like receptor-2 and -4 upregulates 5-LO and 15-LO-2 expression thereby inducing a lipid mediator shift in human monocyte-derived macrophages. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2020, 1865, 158702.

• 25.

  Snodgrass, R.G.; Benatzy, Y.; Schmid, T.; et al. Efferocytosis potentiates the expression of arachidonate 15-lipoxygenase (ALOX15) in alternatively activated human macrophages through LXR activation. Cell Death Differ. 2021, 28, 1301–1316.

• 26.

  Rood, K.M.; Patel, N.; DeVengencie, I.M.; et al. Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells. PLoS ONE 2023, 18, e0283163.

• 27.

  Lukic, A.; Larssen, P.; Fauland, A.; et al. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures. FASEB J. 2017, 31, 4370–4381.

• 28.

  Lehmann, C.; Homann, J.; Ball, A.K.; et al. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein. FASEB J. 2015, 29, 5029–5043.

• 29.

  Herová, M.; Schmid, M.; Gemperle, C.; et al. ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. J. Immunol. 2015, 194, 2330–2337.

• 30.

  Werz, O.; Gerstmeier, J.; Libreros, S.; et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat. Commun. 2018, 9, 59.

• 31.

  Abma, W.; Dahlén, S.E.; Wheelock, C.E.; et al. Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL-13 in human isolated small bronchi. Br. J. Pharmacol. 2025. https://doi.org/10.1111/bph.70298.

• 32.

  Lannan, K.L.; Spinelli, S.L.; Blumberg, N.; et al. Maresin 1 induces a novel pro-resolving phenotype in human platelets. J. Thromb. Haemost. 2017, 15, 802–813.

• 33.

  Kriska, T.; Herrnreiter, A.; Pfister, S.L.; et al. Macrophage 12(S)-HETE Enhances Angiotensin II-Induced Contraction by a BLT2 (Leukotriene B₄ Type-2 Receptor) and TP (Thromboxane Receptor)-Mediated Mechanism in Murine Arteries. Hypertension 2022, 79, 104–114.

• 34.

  Yamaguchi, A.; Stanger, L.; Freedman, C.J.; et al. DHA 12-LOX-derived oxylipins regulate platelet activation and thrombus formation through a PKA-dependent signaling pathway. J. Thromb. Haemost. 2021, 19, 839–851.

• 35.

  Adili, R.; Tourdot, B.E.; Mast, K.; et al. First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1828–1839.

• 36.

  Lundqvist, A.; Sandstedt, M.; Sandstedt, J.; et al. The Arachidonate 15-Lipoxygenase Enzyme Product 15-HETE Is Present in Heart Tissue from Patients with Ischemic Heart Disease and Enhances Clot Formation. PLoS ONE 2016, 11, e0161629.

• 37.

  Hoyer, F.F.; Albrecht, L.; Nickenig, G.; et al. Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE^−/− mice. Mol. Cell Biochem. 2012, 359, 25–31.

• 38.

  Chatterjee, A.; Sharma, A.; Chen, M.; et al. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLoS ONE 2014, 9, e113480.

• 39.

  Edwards-Glenn, J.M.; Fontes, M.T.; Waigi, E.W.; et al. Specialized Pro-resolving Mediator Improves Vascular Relaxation via Formyl Peptide Receptor-2. Am. J. Hypertens. 2023, 36, 542–550.

• 40.

  Olivares-Silva, F.; De Gregorio, N.; Espitia-Corredor, J.; et al. Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension. Biochim. Biophys. Acta Mol. Basis Dis. 2021, 1867, 166241.

• 41.

  Díaz Del Campo, L.S.; García-Redondo, A.B.; Rodríguez, C.; et al. Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension. Hypertension 2023, 80, 84–96.

• 42.

  Hiram, R.; Xiong, F.; Naud, P.; et al. An inflammation resolution-promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction. Cardiovasc. Res. 2024, 120, 345–359.

• 43.

  Bouhadoun, A.; Manikpurage, H.D.; Merheb, G.; et al. Upregulation of the maresin pathway and PGE₂ metabolism in the failing human left ventricle. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2025, 1870, 159645.

• 44.

  Chen, J.W.; Chen, S.L.; Wu, X.R.; et al. 12/15-lipoxygenase mediates disturbed flow-induced endothelial dysfunction and atherosclerosis. Mol. Med. 2025, 31, 257.

• 45.

  Walker, M.E.; De Matteis, R.; Perretti, M.; et al. Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease. Nat. Commun. 2024, 15, 975.

• 46.

  Sather, S.; Kenyon, K.D.; Lefkowitz, J.B.; et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007, 109, 1026–1033.

• 47.

  Olkowicz, M.; Karas, A.; Berkowicz, P.; et al. Upregulation of ALOX12-12-HETE pathway impairs AMPK-dependent modulation of vascular metabolism in ApoE/LDLR^−/− mice. Pharmacol. Res. 2024, 210, 107478.

• 48.

  Lipscomb, M.; Salfate Del Rio, I.; Eid, M.; et al. Resolvin D2 limits senescent cell accumulation in atherosclerotic plaques. Vascul Pharmacol. 2025, 160, 107527.

• 49.

  Laguna-Fernandez, A.; Checa, A.; Carracedo, M.; et al. ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation 2018, 138, 1693–1705.

• 50.

  Bardin, M.; Pawelzik, S.C.; Lagrange, J.; et al. The resolvin D2—GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochem. Pharmacol. 2022, 201, 115075.

• 51.

  Xu, F.; Zhang, J.; Zhou, X.; et al. Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. Exp. Cell Res. 2022, 412, 113025.

• 52.

  Kraft, J.D.; Blomgran, R.; Bergström, I.; et al. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis. FASEB J. 2022, 36, e22173.

• 53.

  Cherpokova, D.; Jouvene, C.C.; Libreros, S.; et al. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood 2019, 134, 1458–1468.

• 54.

  Dienel, A.; Hong, S.H.; Zeineddine, H.A.; et al. 12/15-Lipooxygenase Inhibition Reduces Microvessel Constriction and Microthrombi After Subarachnoid Hemorrhage in Mice. Transl. Stroke Res. 2025, 16, 1156–1172.

• 55.

  Wang, L.; Wang, B. ALOX5 regulates vascular smooth muscle cells pyroptosis to affect abdominal aortic aneurysm formation. Sci. Rep. 2025, 15, 29123.

• 56.

  Elder, C.T.; Filiberto, A.C.; Su, G.; et al. Maresin 1 activates LGR6 signaling to inhibit smooth muscle cell activation and attenuate murine abdominal aortic aneurysm formation. FASEB J. 2021, 35, e21780.

• 57.

  Bouhadoun, A.; Manikpurage, H.D.; Deschildre, C.; et al. DHA, RvD₁, RvD₅, and MaR1 reduce human coronary arteries contractions induced by PGE₂. Prostaglandins Other Lipid Mediat. 2023, 165, 106700.

• 58.

  Rodrigues-Diez, R.; Ballesteros-Martinez, C.; Moreno-Carriles, R.M.; et al. Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors. Biomed. Pharmacother. 2024, 174, 116564.

• 59.

  Miyahara, T.; Runge, S.; Chatterjee, A.; et al. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013, 27, 2220–2232.

• 60.

  Akagi, D.; Chen, M.; Toy, R.; et al. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015, 29, 2504–2513.

• 61.

  Makino, Y.; Miyahara, T.; Nitta, J.; et al. Proresolving Lipid Mediators Resolvin D1 and Protectin D1 Isomer Attenuate Neointimal Hyperplasia in the Rat Carotid Artery Balloon Injury Model. J. Surg. Res. 2019, 233, 104–110.

• 62.

  Kim, A.S.; Werlin, E.C.; Kagaya, H.; et al. 17R/S-Benzo-RvD₁, a synthetic resolvin D1 analogue, attenuates neointimal hyperplasia in a rat model of acute vascular injury. PLoS ONE 2022, 17, e0264217.

• 63.

  Mottola, G.; Werlin, E.C.; Wu, B.; et al. Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model. Prostaglandins Other Lipid Mediat. 2020, 146, 106401.

• 64.

  Kagaya, H.; Kim, A.S.; Chen, M.; et al. Dynamic changes in proresolving lipid mediators and their receptors following acute vascular injury in male rats. Physiol. Rep. 2024, 12, e16178.

• 65.

  Celik, Z.; Ozen, G.; Sunar, S.; et al. Effect of specialized pro-resolving lipid mediators in the regulation of vascular tone and inflammation in human saphenous vein. Prostaglandins Other Lipid Mediat. 2023, 169, 106786.

• 66.

  Cai, W.; Liu, L.; Shi, X.; et al. Alox15/15-HpETE Aggravates Myocardial Ischemia-Reperfusion Injury by Promoting Cardiomyocyte Ferroptosis. Circulation 2023, 147, 1444–1460.

• 67.

  Kain, V.; Ingle, K.A.; Kabarowski, J.; et al. Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction. J. Mol. Cell Cardiol. 2018, 118, 70–80.

• 68.

  Fabre, P.; Molina, T.; Larose, J.; et al. Bioactive lipid mediator class switching regulates myogenic cell progression and muscle regeneration. Nat. Commun. 2025, 16, 5578.

• 69.

  Freedman, C.; Tran, A.; Tourdot, B.E.; et al. Biosynthesis of the Maresin Intermediate, 13S,14S-Epoxy-DHA, by Human 15-Lipoxygenase and 12-Lipoxygenase and Its Regulation through Negative Allosteric Modulators. Biochemistry 2020, 59, 1832–1844.

• 70.

  Kutzner, L.; Goloshchapova, K.; Rund, K.M.; et al. Human lipoxygenase isoforms form complex patterns of double and triple oxygenated compounds from eicosapentaenoic acid. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2020, 1865, 158806.

• 71.

  Rao, Z.; Brunner, E.; Giszas, B.; et al. Glucocorticoids regulate lipid mediator networks by reciprocal modulation of 15-lipoxygenase isoforms affecting inflammation resolution. Proc. Natl. Acad. Sci. USA 2023, 120, e2302070120.

• 72.

  Reinertsen, A.F.; Primdahl, K.G.; De Matteis, R.; et al. Stereoselective Synthesis, Configurational Assignment and Biological Evaluations of the Lipid Mediator RvD2_n-3 DPA. Chemistry 2022, 28, e202103857.

• 73.

  Ervik, K.; Reinertsen, A.F.; Koenis, D.S.; et al. Stereoselective Synthesis, Pro-resolution, and Anti-inflammatory Actions of RvD5_n-3 DPA. J. Nat. Prod. 2023, 86, 2546–2553.

• 74.

  Sønderskov, J.; Tungen, J.E.; Palmas, F.; et al. Stereoselective synthesis of MaR2_n-3 DPA. Tetrahedron Lett. 2020, 61, 151510.

• 75.

  Tungen, J.E.; Primdahl, K.G.; Hansen, T.V. The First Total Synthesis of the Lipid Mediator PD2_n-3 DPA. J. Nat. Prod. 2020, 83, 2255–2260.

• 76.

  Merlin, J.; Park, J.; Vandekolk, T.H.; et al. Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors. Mol. Pharmacol. 2022, 101, 246–256.

• 77.

  Flak, M.B.; Koenis, D.S.; Sobrino, A.; et al. GPR101 mediates the pro-resolving actions of RvD5_n-3 DPA in arthritis and infections. J. Clin. Investig. 2020, 130, 359–373.

• 78.

  Kozłowska, H.; Malinowska, B.; Baranowska-Kuczko, M.; et al. GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries. Int. J. Mol. Sci. 2022, 23, 1427.

• 79.

  Bellotti, P.; Ladd, Z.; Leroy, V.; et al. Resolvin D2/GPR18 signaling enhances monocytic myeloid-derived suppressor cell function to mitigate abdominal aortic aneurysm formation. FASEB J. 2024, 38, e70067.

• 80.

  Pistorius, K.; Souza, P.R.; De Matteis, R.; et al. PD_n-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function. Cell Chem. Biol. 2018, 25, 749–760.e9.

• 81.

  Galvão, I.; Melo, E.M.; de Oliveira, V.L.S.; et al. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. Pharmacol. Res. 2021, 165, 105445.

• 82.

  Serhan, C.N.; Hamberg, M.; Samuelsson, B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 1984, 81, 5335–5339.

• 83.

  Serhan, C.N.; Sheppard, K.A. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Investig. 1990, 85, 772–780.

• 84.

  Naruhn, S.; Meissner, W.; Adhikary, T.; et al. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist, Mol. Pharmacol. 2010, 77, 171–184.

• 85.

  Thankam, F.G.; Wilson, V.E.D.; Radwan, M.M.; et al. Involvement of ischemia-driven 5-lipoxygenase-resolvin-E1-chemokine like receptor-1 axis in the resolution of post-coronary artery bypass graft inflammation in coronary arteries. Mol. Biol. Rep. 2022, 49, 3123–3134.

• 86.

  Liu, G.; Wan, N.; Liu, Q.; et al. Resolvin E1 Attenuates Pulmonary Hypertension by Suppressing Wnt7a/β-Catenin Signaling. Hypertension 2021, 78, 1914–1926.

• 87.

  Arita, M.; Bianchini, F.; Aliberti, J.; et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201, 713–722.

• 88.

  Tjonahen, E.; Oh, S.F.; Siegelman, J.; et al. Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 2006, 13, 1193–1202.

• 89.

  Isobe, Y.; Arita, M.; Matsueda, S.; et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J. Biol. Chem. 2012, 287, 10525–10534.

• 90.

  Reinertsen, A.F.; Primdahl, K.G.; Shay, A.E.; et al. Stereoselective Synthesis and Structural Confirmation of the Specialized Pro-Resolving Mediator Resolvin E4. J. Org. Chem. 2021, 86, 3535–3545.

• 91.

  Perry, S.C.; van Hoorebeke, C.; Sorrentino, J.; et al. Structural basis for altered positional specificity of 15-lipoxygenase-1 with 5S-HETE and 7S-HDHA and the implications for the biosynthesis of resolvin E4. Arch. Biochem. Biophys. 2022, 727, 109317.

• 92.

  Ogawa, N.; Sugiyama, T.; Morita, M.; et al. Total Synthesis of Resolvin D5. J. Org. Chem. 2017, 82, 2032–2039.

• 93.

  Shay, A.E.; Nshimiyimana, R.; Samuelsson, B.; et al. Human leukocytes selectively convert 4S,5S-epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer. Proc. Natl. Acad. Sci. USA 2021, 118, e2116559118.

• 94.

  Vara-Messler, M.; Trevisi, L.; Zulato, E.; et al. Aspirin-triggered DHA metabolites inhibit angiogenesis. Front. Pharmacol. 2025, 16, 1524980.

• 95.

  Rodriguez, A.R.; Spur, B.W. First total syntheses of the pro-resolving lipid mediators 7(S),13(R),20(S)-Resolvin T1 and 7(S),13(R)-Resolvin T4. Tetrahedron Lett. 2020, 61, 151473.

• 96.

  Aursnes, M.; Tungen, J.E.; Vik, A.; et al. Stereoselective synthesis of protectin D1: A potent anti-inflammatory and proresolving lipid mediator. Org. Biomol. Chem. 2014, 12, 432–437.

• 97.

  Tsai, W.C.; Kalyanaraman, C.; Yamaguchi, A.; et al. In Vitro Biosynthetic Pathway Investigations of Neuroprotectin D1 (NPD1) and Protectin DX (PDX) by Human 12-Lipoxygenase, 15-Lipoxygenase-1, and 15-Lipoxygenase-2. Biochemistry 2021, 60, 1741–1754.

• 98.

  Bang, S.; Xie, Y.K.; Zhang, Z.J.; et al. GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. J. Clin. Investig. 2018, 128, 3568–3582.

• 99.

  Shin, K.-C.; Lee, T.-E.; Kim, S.-E.; et al. Enzymatic Formation of Protectin Dx and Its Production by Whole-Cell Reaction Using Recombinant Lipoxygenases. Catalysts 2022, 12, 1145.

• 100.

  Lee, T.E.; Ko, Y.J.; Shin, K.C.; et al. Biotransformation of docosahexaenoic acid into 10R,17S-dihydroxydocosahexaenoic acid as protectin DX 10-epimer by serial reactions of arachidonate 8R- and 15S-lipoxygenases. World J. Microbiol. Biotechnol. 2024, 40, 219.

• 101.

  Sugimoto, S.; Mena, H.A.; Sansbury, B.E.; et al. Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation. Nat. Metab. 2022, 4, 775–790.

• 102.

  Chiang, N.; Libreros, S.; Norris, P.C.; et al. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J. Clin. Invest. 2019, 129, 5294–5311.

• 103.

  Sorokin, A.V.; Arnardottir, H.; Svirydava, M.; et al. Comparison of the dietary omega-3 fatty acids impact on murine psoriasis-like skin inflammation and associated lipid dysfunction. J. Nutr. Biochem. 2023, 117, 109348.

• 104.

  Szczuko, M.; Kacprzak, J.; Przybylska, A.; et al. The Influence of an Anti-Inflammatory Gluten-Free Diet with EPA and DHA on the Involvement of Maresin and Resolvins in Hashimoto’s Disease. Int. J. Mol. Sci. 2024, 25, 11692.

• 105.

  Dalli, J.; Vlasakov, I.; Riley, I.R.; et al. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proc. Natl. Acad. Sci. USA 2016, 113, 12232–12237.

• 106.

  Hong, S.; Lu, Y.; Tian, H.; et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. Chem. Biol. 2014, 21, 1318–1329.

• 107.

  Spanbroek, R.; Grabner, R.; Lotzer, K.; et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 1238–1243.

• 108.

  Di Gennaro, A.; Wågsäter, D.; Mäyränpää, M.I.; et al. Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc. Natl. Acad. Sci. USA 2010, 107, 21093–21097.

• 109.

  Maga, P.; Wachsmann-Maga, A.; Włodarczyk, A.; et al. Leukotrienes E4 and B4 and vascular endothelium—New insight into the link between vascular inflammation and peripheral arterial. Int. J. Cardiol. Cardiovasc. Risk Prev. 2024, 23, 200343.

• 110.

  Vidal, C.; Gómez-Hernández, A.; Sánchez-Galán, E.; et al. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J. Pharmacol. Exp. Ther. 2007, 320, 108–116.

• 111.

  Matsumoto, S.; Ibrahim, R.; Grégoire, J.C.; et al. Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: A serial CT angiography study. Clin. Cardiol. 2017, 40, 210–215.

• 112.

  Hakonarson, H.; Thorvaldsson, S.; Helgadottir, A.; et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial. JAMA 2005, 293, 2245–2256.

• 113.

  Knöchel, J.; Nelander, K.; Heijer, M.; et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects. Clin. Drug Investig. 2021, 41, 895–905.

• 114.

  Ericsson, H.; Nelander, K.; Heijer, M.; et al. Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability. Clin. Pharmacol. Drug Dev. 2020, 9, 411–421.

• 115.

  Prescott, E.; Angerås, O.; Erlinge, D.; et al. Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. Int. J. Cardiol. 2022, 365, 34–40.

• 116.

  Perry, S.C.; Kalyanaraman, C.; Tourdot, B.E.; et al. 15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5. J. Lipid Res. 2020, 61, 1087–1103.

• 117.

  Werner, M.; Jordan, P.M.; Romp, E.; et al. Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB J. 2019, 33, 6140–6153.

• 118.

  Jannaway, M.; Torrens, C.; Warner, J.A.; et al. Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619. Br. J. Pharmacol. 2018, 175, 1100–1108.

• 119.

  Viola, J.R.; Lemnitzer, P.; Jansen, Y.; et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ. Res. 2016, 119, 1030–1038.

• 120.

  Petri, M.H.; Laguna-Fernandez, A.; Arnardottir, H.; et al. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E^−/− mice. Br. J. Pharmacol. 2017, 174, 4043–4054.

• 121.

  Filiberto, A.C.; Ladd, Z.; Leroy, V.; et al. Resolution of inflammation via RvD1/FPR2 signaling mitigates Nox2 activation and ferroptosis of macrophages in experimental abdominal aortic aneurysms. FASEB J. 2022, 36, e22579.

• 122.

  Hasturk, H.; Abdallah, R.; Kantarci, A.; et al. Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 1123–1133.

• 123.

  Salic, K.; Morrison, M.C.; Verschuren, L.; et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 2016, 250, 158–165.

• 124.

  Elajami, T.K.; Colas, R.A.; Dalli, J.; et al. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016, 30, 2792–2801.

• 125.

  Bazan, H.A.; Lu, Y.; Jun, B.; et al. Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease. Prostaglandins Leukot. Essent. Fatty Acids 2017, 125, 43–47.

• 126.

  Yuan, M.; Zhang, Y.; Hua, T.; et al. Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial. Clin. Nutr. 2021, 40, 445–459.

• 127.

  Bhatt, D.L.; Steg, P.G.; Miller, M.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med. 2019, 380, 11–22.

• 128.

  Budoff, M.J.; Bhatt, D.L.; Kinninger, A.; et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: Final results of the EVAPORATE trial. Eur. Heart J. 2020, 41, 3925–3932.

• 129.

  Souza, P.R.; Marques, R.M.; Gomez, E.A.; et al. Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study. Circ. Res. 2020, 126, 75–90.

• 130.

  Ostermann, A.I.; West, A.L.; Schoenfeld, K.; et al. Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: Results from a randomized controlled trial in healthy humans. Am. J. Clin. Nutr. 2019, 109, 1251–1263.

• 131.

  Schaller, M.S.; Chen, M.; Colas, R.A.; et al. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. J. Am. Heart Assoc. 2020, 9, e016113.

• 132.

  Ramirez, J.L.; Gasper, W.J.; Khetani, S.A.; et al. Fish oil increases specialized pro-resolving lipid mediators in PAD (the OMEGA-PAD II Trial). J. Surg. Res. 2019, 238, 164–174.

• 133.

  Nicholls, S.J.; Lincoff, A.M.; Garcia, M.; et al. Effect of High-Dose Omega-3 Fatty Acids vs. Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020, 324, 2268–2280.

• 134.

  Garscha, U.; Voelker, S.; Pace, S.; et al. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly. Biochem. Pharmacol. 2016, 119, 17–26.

• 135.

  Kretzer, C.; Jordan, P.M.; Bilancia, R.; et al. Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201. J. Inflamm. Res. 2022, 15, 911–925.

• 136.

  Schoenthaler, M.; Waltl, L.; Hasenoehrl, T.; et al. Novel thiazolopyridine derivatives of diflapolin as dual sEH/FLAP inhibitors with improved solubility. Bioorg. Chem. 2023, 139, 106685.